Page last updated: 2024-09-02
thromboxanes and ra 642
thromboxanes has been researched along with ra 642 in 1 studies
Compound Research Comparison
| Studies (thromboxanes) | Trials (thromboxanes) | Recent Studies (post-2010) (thromboxanes) | Studies (ra 642) | Trials (ra 642) | Recent Studies (post-2010) (ra 642) |
|---|---|---|---|---|---|
| 3,202 | 149 | 199 | 20 | 0 | 0 |
Research
Studies (1)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| De La Cruz, JP; García Campos, J; Mérida, F; Moreno, A; Sánchez de la Cuesta, F | 1 |
Other Studies
1 other study(ies) available for thromboxanes and ra 642
| Article | Year |
|---|---|
The pyrimido-pyrimidine derivatives, dipyridamole, mopidamol and RA-642, prevent from retinal vascular defects in experimental diabetes mellitus.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetic Retinopathy; Dipyridamole; Epoprostenol; Male; Mopidamol; Neovascularization, Pathologic; Platelet Aggregation Inhibitors; Pyrimidines; Rats; Rats, Wistar; Thromboxanes | 1996 |